In the STEP 1 trial, adults with overweight or obesity without diabetes treated with once-weekly semaglutide at 2.4 mg led to approximately 14.9% mean weight loss at 68 weeks compared to approximately 2.4% with placebo alongside lifestyle interventions, GI side effects were common and discontinuation due to GI events was higher with semaglutide, and STEP 1 trial showed improvements across a range of cardiometabolic markers.
factualpending
Speaker
Dr. Amin DadgarEvidence Quote
“In the STEP 1 trial, adults with overweight or obesity without diabetes, once-weekly semaglutide at the dose of 2.4 mg led to about 14.9% mean weight loss”
Created: 8/12/2026, 6:40:36 PM
Your notes
Loading notes...